All clinical trials of new medicines in New Zealand require approval from Medsafe and an ethics committee, and Medsafe has not approved any clinical trials in New Zealand for these products
This ultra-low starting dose is designed for patients with high sensitivity to GLP-1 medications, those who have experienced severe side effects on semaglutide or other GLP-1 medications , or patients who want the most gradual possible introduction
Activation of human acid sphingomyelinase through modification or deletion of C-terminal cysteine
Diabetes, cardiovascular disease, and obesity are independent risk factors for kidney disease and represent a major global health burden
The pursuit of a tan has always carried risks, but injecting an unregulated peptide to achieve a tan raises those risks significantly, she says
Looking For Smarter Solutions There are many other affordable ways to see better results without having to inject yourself with GLP-1 drugs